Data as of Oct 28, 2026.

vsCompare their flowsaskIQ about these two fundsAsk the committee about these two funds
Across categories

VGLT vs XBI: Differences, Returns & Fees

Share
Share on XDownload as PDF

Over the year to Oct 28, 2026, VGLT returned −6.7% to XBI's +41.2%, and VGLT charges 0.03% to XBI's 0.35%.

askIQ about this page

askIQ about VGLT and XBI

Net assets: $10.4bn on Sep 30, 2026 for Vanguard Long-Term Treasury ETF, and $10.3bn on Oct 27, 2026 for State Street SPDR S&P Biotech ETF.

At a glance
−6.7%
VGLT total return, 1 year
+41.2%
XBI total return, 1 year
0.03%
VGLT expense ratio
0.35%
XBI expense ratio

Pair scorecard

VGLT costs 0.32 points a year less; their one-year returns differ by 47.9 points.

VGLT vs XBI: Differences, Returns & Fees
MeasureVGLTXBI
Return
Total return, 1 year−6.7%+41.2%
Drawdown
Below its high38.8%, high on Aug 4, 2020
Below its all-time high8.9%, high on Feb 8, 2021
Benchmark
What it tracksBloomberg U.S. Long Treasury IndexBiotech
Cost and size
Expense ratio0.03%0.35%
Net assets, as of Sep 30, 2026$10.4bn$10.4bn
Active share vs the S&P 50098%
Holdings
Holdings in common0%
In the S&P 500, by weight13%
Top ten holdings, share of the fund18%

Holdings in common uses holdings dated Sep 30, 2026 and Oct 27, 2026. Method

What they share

0%

By the books each fund has filed, VGLT and XBI hold 0% of their money in the same securities at the same weight. Holdings dated Sep 30, 2026 and Oct 27, 2026.

0 half 100%

half

0% in common

Positions both hold · largest shared weight first VGLT XBI
Only in one fund ↓
Only in VGLT
United States Treasury Note/Bond 2.19%
United States Treasury Note/Bond 2.13%
United States Treasury Note/Bond 2.13%
United States Treasury Note/Bond 2.10%
United States Treasury Note/Bond 2.08%
United States Treasury Note/Bond 2.08%
United States Treasury Note/Bond 2.07%
United States Treasury Note/Bond 2.05%
Only in XBI
MODERNA INC 2.24%
TWIST BIOSCIENCE CORP 1.86%
NATERA INC 1.82%
BIOGEN INC 1.75%
HALOZYME THERAPEUTICS INC 1.75%
UNITED THERAPEUTICS CORP 1.71%
AMGEN INC 1.68%
ABBVIE INC 1.67%
Check overlap with more funds →

Side by side

VGLT Vanguard Long-Term Treasury ETF XBI State Street SPDR S&P Biotech ETF
Where it sits Bond ETF Thematic ETF
What it is Tracks an index of Long-term Treasury Biotech
Total return, 1 year −6.7% +41.2%
Its benchmark over the same days −6.7% (SCHQ) not measured
Gap to its benchmark 0.0 pts vs SCHQ not measured
Expense ratio 0.03% 0.35%
Holdings 102 165
Net assets, VGLT as of Sep 30, 2026 and XBI as of Oct 27, 2026 $10.4bn $10.3bn

VGLT and XBI on the fields both publish, as of Oct 28, 2026. Source: ETFIQ.

Alert

XBI flows, by email on Sundays.

One-click unsubscribe. See Privacy.

About each fund
VGLT

VGLT tracks an index of Long-term Treasury. Over the year to Oct 28, 2026 it returned −6.7% with distributions reinvested, against −6.7% for its benchmark, the Bloomberg U.S. Long Treasury Index. The prospectus expense ratio is 0.03% a year. It sat 38.8% below its high of Aug 4, 2020 on Oct 28, 2026.

XBI

By weight, 13% of XBI's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 18% of the fund across 165 positions, as published by its issuer for Oct 27, 2026. Over the year to Oct 28, 2026 the fund returned +41.2% with distributions reinvested. It sits 8.9% below its all-time high of Feb 8, 2021.

Questions people ask

Are VGLT and XBI in the same category?
VGLT is a bond ETF and XBI is a thematic ETF, so they do different jobs. The table compares what both publish: return, cost and holdings.
Which returned more over the last year, VGLT or XBI?
In the year to Oct 28, 2026, with distributions reinvested, VGLT returned −6.7% and XBI +41.2%.
Which is cheaper, VGLT or XBI?
VGLT is cheaper, by 0.32 percentage points a year. That is about $32 on $10,000 held for a year. Fees come from each fund's prospectus.
Other comparisons
Cite this pageCitation, APA and Markdown

ETFIQ, VGLT against XBI, data as of Oct 28, 2026. https://etfiq.com/compare/any/vglt-vs-xbi

Open data →

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.